Friday 6 November 2026 Export LGND’s income statement to Excel — free account

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $268.1 million, up 60.4% from fiscal 2024.

Revenue: −31.8%
EPS: −123.9%
Free cash flow: −268.5%
Total debt: +52.6%

Quarter to September 2026, against a year earlier

306.43 7.43 +2.48%

Follow LGND

Alert me

Market cap: $6.0B
P/E: 116×
Fwd P/E: 88.3×
Dividend yield: —
F-score: 6/9
Altman Z: 5.45
Beneish M: −4.02
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Ligand Pharmaceuticals Incorporated (LGND) Price to free cash flow

Alert me on Price to free cash flow

As of 5 November 2026, Ligand Pharmaceuticals Incorporated (LGND) trades at a price to free cash flow of 58.0×. Over the past ten years it has ranged from 0.0× (September 2024) to 228× (October 2019); the current reading is higher than 87% of that period. That is above the Biotechnology industry median of 24.8× and above the Healthcare sector median of 21.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/LGND/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="Ligand Pharmaceuticals Incorporated price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/LGND/metrics/price-to-free-cash-flow">Ligand Pharmaceuticals Incorporated (LGND) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	60.0×	174.81%
FY2024	21.8×	—
FY2023	0.0×	—
FY2022	10.0×	(62.26%)
FY2021	26.4×	13.06%
FY2020	23.3×	—
FY2019	0.0×	—
FY2018	10.7×	(50.93%)
FY2017	21.8×	(40.62%)
FY2016	36.7×	0.38%

Period	Price to free cash flow	Change
Sep 2026	60.3×	36.36%
Jun 2026	44.2×	49.97%
Mar 2026	29.5×	(50.86%)
Dec 2025	60.0×	(54.60%)
43 more quarters	Free account

Against its own ten years

Low 0.0× High 228×

Ten-year median 33.6×

Current reading's percentile 87

Company	Price to free cash flow
BLTE Belite Bio, Inc. Sponsored ADR compare	n/m
MIRM Mirum Pharmaceuticals, Inc. compare	n/m
CGON CG Oncology, Inc. compare	n/m
IMVT Immunovant, Inc. compare	n/m
IONS Ionis Pharmaceuticals, Inc. compare	n/m
ORKA Oruka Therapeutics, Inc. compare	n/m
PTCT PTC Therapeutics, Inc. compare	n/m
KOD Kodiak Sciences Inc. compare	n/m
LGND Ligand Pharmaceuticals Incorporated	58.0×
Biotechnology industry median	24.8×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

Ligand Pharmaceuticals Incorporated (LGND) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on LGND

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on LGND

Stockrow Weekly